Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRuth CliffordCMClifton C. MoSKSenthil Kumar

Discussion

Loading...

Member takes

Overview

Phase 2 studies show high VGPR rates with Isa-RVd, suggesting its viability as induction therapy for multiple myeloma.

Key Points

  • Evaluate the efficacy and safety of Isatuximab-RVd as induction therapy in multiple myeloma patients eligible for transplant.
  • Conducted two parallel phase 2 studies with patients aged 18–75 years.
  • Administered two 42-day induction cycles of Isatuximab-RVd.
  • Monitored minimal residual disease and treatment-emergent adverse events.
  • ≥ Very good partial response rate of 61.9% in the DFCI study and 89.8% in the CTI study after two cycles.
  • 95.2% overall response rate in the DFCI study and 98.0% in the CTI study.
  • 37.5% of patients achieved MRD-negative status in the CTI study.

Cite This Study

Clifford et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da7dhttps://doi.org/10.1182/blood-2025-4030
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P13 | ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT: FINAL ANALYSIS OF A PHASE 2 STUDY BY GREEK MYELOMA STUDY GROUP2026
  2. 2P15 | RANDOMIZED COMPARISON OF ISATUXIMAB–RD INDUCTION FOLLOWED BY ISA R MAINTENANCE VS. RD INDUCTION FOLLOWED BY R MAINTENANCE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (AGMT MM04 TRIAL)2026
  3. 3Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).2024 · 3 citations
  4. 4Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group2025
  5. 5Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)2025 · 1 citations